Molecular Templates

Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariépy, and Leigh Revers in 2000 and is headquartered in Austin, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariépy, and Leigh Revers in 2001 and is headquartered in Austin, TX.

AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the second quarter of 2021.

Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results

Molecular Templates Inc. (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Molecular Templates Inc. (MTEM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

AUSTIN, Texas, July 09, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced the dosing of the first subject in a Phase 1 study investigating MT-6402 in patients with PD-L1-positive solid tumors.

Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -282.14% and -89.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Molecular Templates Inc. (MTEM) Reports Q1 Loss, Lags Revenue Estimates

AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2021.

Molecular Templates, Inc. Reports First Quarter 2021 Financial Results

Posters will feature data on MT-5111 (targeting HER2), MT-6402 (targeting PD-L1) and a novel CTLA-4-targeted ETB Posters will feature data on MT-5111 (targeting HER2), MT-6402 (targeting PD-L1) and a novel CTLA-4-targeted ETB

Molecular Templates Announces Poster Presentations on its Engineered Toxin Bodies at the American Association of Cancer Research (AACR) Virtual Annual Meeting I

The company is taking back rights to one drug candidate and discontinuing development of another.

Why Molecular Templates Stock Crashed Today

Molecular Templates Inc (NASDAQ: MTEM) has decided to discontinue the development of MT-3724, its only first-generation engineered toxin bodies (ETB), and focus its resources on the development of next-generation ETBs. In November last year, FDA instituted a partial clinical hold on Phase 2 MT-3724 monotherapy study following a treatment-related fatality in one subject who experienced Grade 5 capillary leak syndrome.

Molecular Templates Stock Falls After It Stops MT-3724 Development In Hematological Malignancies

Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma

Molecular Templates to Prioritize Next-Generation ETB Candidates

AUSTIN, Texas, March 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the fourth quarter of 2020.

Molecular Templates, Inc. Reports Fourth Quarter 2020 Financial Results

Agree Realty

Avis Budget Group

Zoetis

American Assets

Incyte

OPKO Health

Royalty Pharma

Sonos

United States Lime & Minerals, Inc.

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases this week.

The Past Week's Notable Insider Buys: Agree Realty, Avis Budget, Zoetis And More

Bumble

Fiserv

Anterix Inc

Corvus Pharmaceuticals

Decibel Therapeautics

NexImmune

Oncorus

Prothena

Talis Biomedical

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More

Invitae

Veru

Community Health Systems

Community Health Systems (NYSE: CYH) shares are trading higher after the company reported better-than-expected fourth-quarter sales results. Community Health Systems is the largest publicly owned hospital operator in the United States.

Why Veru, Invitae And More Are Moving Today

AUSTIN, Texas, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company's proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that it has commenced an underwritten public offering of its common stock. Molecular also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All of the shares in the offering are to be sold by Molecular.

Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock

Molecular Templates to receive $70 million upfront payment with potential for additional milestone and royalty payments on future sales Molecular Templates to receive $70 million upfront payment with potential for additional milestone and royalty payments on future sales

Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer

Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to Begin When MTD or Recommended Phase 2 Dose is Reached

Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study

AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company's proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that it will deliver presentations and participate in 1on1 meetings at the Stifel 2020 Virtual Healthcare Conference and the 3rd Annual Evercore ISI HealthCONx Conference. In addition, management will be available for virtual 1on1 meetings at the Jefferies Virtual London Healthcare Conference.

Molecular Templates to Participate in Upcoming Virtual Investor Conferences

AUSTIN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the third quarter of 2020 and an update on its clinical pipeline.

Molecular Templates, Inc. Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

AUSTIN, Texas, Sept.  03, 2020  (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that it will deliver presentations at the Cantor Fitzgerald Virtual Global Healthcare Conference and the Morgan Stanley 18th Annual Global Healthcare Conference. In addition, management will be available for virtual 1on1 meetings at the Citi 15th Annual BioPharma Virtual Conference and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

Molecular Templates to Participate in September Virtual Investor Conferences

AUSTIN, Texas, Aug.  06, 2020  (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the second quarter of 2020.

Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results

AUSTIN, Texas, July  20, 2020  (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that it has raised gross proceeds of approximately $43 million through its At-the-Market facility (“ATM”) with participation based on interest received from Consonance Capital Management. The Company sold approximately 3.6 million shares of the Company’s common stock at a purchase price of $12.00, the market price at the time of sale. Cantor Fitzgerald & Co. is acting as the sales agent for the ATM.

Molecular Templates, Inc. Raises $43 Million in Gross Proceeds Through Its At-the-Market Facility

Update Provided Phase I Study of MT-5111 in HER2-positive Cancers

Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2020 Highlight Evolution of ETB Platform

Molecular Templates: Updates To Thesis, Pursuing Validated Targets With Unique MOA

AUSTIN, Texas, May  22, 2020  (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced it has secured a debt financing facility for up to $45 million from K2 HealthVentures, a healthcare-focused specialty finance company. MTEM received a first tranche of $15 million upon closing, a portion of which has been used to repay the remaining indebtedness that was outstanding under the Company’s prior credit facility. Two subsequent tranches totaling up to $30 million will become available to MTEM, at its option, upon the achievement of certain milestones with respect to the second tranche and, subject to lender consent and certain additional conditions with respect to the third tranche.

Molecular Templates, Inc. Announces $45 Million Debt Financing From K2 HealthVentures

As of late, it has definitely been a great time to be an investor Molecular Templates

Will Molecular Templates Continue to Surge Higher?

News for Molecular Templates Stock (MTEM)